Hippocratic AI has secured $126m in a Series C funding round for the expansion of clinically safe generative AI (genAI) agents across healthcare.
This funding values the company at $3.5bn and raises its total to $404m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Avenir Growth led the round with participation from entities that include General Catalyst, Kleiner Perkins, Premji Invest, and WellSpan Health.
Hippocratic AI claims that within 15 months of its commercial launch, it has formed partnerships with more than 50 health systems, pharmaceutical clients, and payers across six countries.
The company has conducted over 115 million clinical patient interactions without any safety issues and developed more than 1,000 clinical use cases.
Avenir Growth co-founder Andrew Sugrue said: “At Avenir, we focus on investing in category leaders. After speaking with a significant number of customers prior to investing, we believe Hippocratic AI is leading the agentic healthcare category.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Importantly, we found that their relentless focus on safety has earned them the trust of healthcare organisations around the world, becoming the safe choice for executives when choosing AI agents for deployment in healthcare.”
Hippocratic AI co-founder and CEO Munjal Shah said: “Every call our agents make is a patient whose life we have helped to make healthier. We truly believe that generative AI agents can help bring in an era of abundance to healthcare never seen before.”
The funding will accelerate customer deployments globally and enables the company to continue making investments in Polaris Safety Constellation Architecture.
Additionally, the proceeds will facilitate strategic mergers and acquisitions.
Earlier this year, Hippocratic AI completed its Series B financing round, raising $141m to broaden its reach to new verticals, including the pharmaceutical sector and payors, as well as for market expansion.
